1. Home
  2. STXS vs MXCT Comparison

STXS vs MXCT Comparison

Compare STXS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$1.29

Market Cap

164.1M

Sector

Health Care

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.11

Market Cap

136.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STXS
MXCT
Founded
1990
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.1M
136.0M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
STXS
MXCT
Price
$1.29
$1.11
Analyst Decision
Strong Buy
Buy
Analyst Count
2
4
Target Price
$4.00
$5.50
AVG Volume (30 Days)
1.1M
1.7M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$29,346,617.00
$33,026,000.00
Revenue This Year
$28.22
N/A
Revenue Next Year
$30.47
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$0.64
52 Week High
$3.59
$2.31

Technical Indicators

Market Signals
Indicator
STXS
MXCT
Relative Strength Index (RSI) 24.76 38.61
Support Level N/A $1.08
Resistance Level $1.98 $1.16
Average True Range (ATR) 0.14 0.09
MACD -0.03 -0.03
Stochastic Oscillator 0.76 6.10

Price Performance

Historical Comparison
STXS
MXCT

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: